Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol
使用 RV-SFG.CD19.CD28.4-1BBzeta 逆转录病毒载体转导的 T 淋巴细胞治疗复发或难治性 CD19+ 淋巴瘤患者:一项单中心 I/II 期临床试验方案
期刊:BMJ Open
影响因子:2.3
doi:10.1136/bmjopen-2018-026644
Schubert, Maria-Luisa; Schmitt, Anita; Sellner, Leopold; Neuber, Brigitte; Kunz, Joachim; Wuchter, Patrick; Kunz, Alexander; Gern, Ulrike; Michels, Birgit; Hofmann, Susanne; Hückelhoven-Krauss, Angela; Kulozik, Andreas; Ho, Anthony D; Müller-Tidow, Carsten; Dreger, Peter; Schmitt, Michael
信号转导
微生物学
CD28
CD19
CD2
淋巴瘤
细胞生物学